{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:41:12Z","timestamp":1778539272346,"version":"3.51.4"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["5360-ccfc"],"award-info":[{"award-number":["5360-ccfc"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["336431, 336410"],"award-info":[{"award-number":["336431, 336410"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009094","name":"Turun Yliopistollisen Keskussairaalan Koulutus- ja Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008309","name":"Hengityssairauksien Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008309","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Primary antibody deficiencies, such as common variable immunodeficiency (CVID), are heterogenous disease entities consisting of primary hypogammaglobulinemia and impaired antibody responses to vaccination and natural infection. CVID is the most common primary immunodeficiency in adults, presenting with recurrent bacterial infections, enteropathy, autoimmune disorders, interstitial lung diseases and increased risk of malignancies. Patients with CVID are recommended to be vaccinated against SARS-CoV-2, but there are relatively few studies investigating humoral and cellular responses to immunization. We studied the dynamics of humoral and cell-mediated immunity responses up to 22 months in 28 patients with primary immunodeficiency and three patients with secondary immunodeficiency receiving ChAdOx1, BNT162b2 and mRNA-1273 COVID-19 vaccines. Despite inadequate humoral response to immunization, we demonstrate a robust T cell activation likely protecting from severe COVID-19.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1146500","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T20:40:35Z","timestamp":1683751235000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["T cell immunity following COVID-19 vaccination in adult patients with primary antibody deficiency \u2013 a 22-month follow-up"],"prefix":"10.3389","volume":"14","author":[{"given":"Antti","family":"Hurme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinja","family":"Jalkanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minna","family":"Marttila-Vaara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jemna","family":"Heroum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Jokinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saimi","family":"Vara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oona","family":"Liedes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Lempainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merit","family":"Melin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilkka","family":"Julkunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leena","family":"Kainulainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.06.019","article-title":"Common variable immunodeficiency disorders, T-cell responses to SARS-CoV-2 vaccines, and the risk of chronic COVID-19","volume":"9","author":"Ameratunga","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00928-x","article-title":"Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency","volume":"41","author":"Delavari","year":"2021","journal-title":"J Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abo2202","article-title":"Divergent SARS-CoV-2 omicron\u2013reactive T and b cell responses in COVID-19 vaccine recipients","volume":"7","author":"GeurtsvanKessel","year":"2022","journal-title":"Sci Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.869990","article-title":"Long-lasting T cell responses in BNT162b2 COVID-19 mRNA vaccinees and COVID-19 convalescent patients","volume":"13","author":"Hurme","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.760249","article-title":"The humoral immune response to BNT162b2 vaccine is associated with circulating CD19+ b lymphocytes and the na\u00efve CD45RA to memory CD45RO CD4+ T helper cells ratio in hemodialysis patients and kidney transplant recipients","volume":"12","author":"Duni","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41419-022-05190-0","article-title":"Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients","volume":"13","author":"Andr\u00e9","year":"2022","journal-title":"Cell Death Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh361","article-title":"Peptide-induced immune protection of CD8+ T cell-deficient mice against friend retrovirus-induced disease","volume":"18","author":"Kawabata","year":"2006","journal-title":"Int Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048745","article-title":"CD8+ T cells are crucial for humoral immunity establishment by SA14-14-2 live attenuated Japanese encephalitis vaccine in mice","volume":"51","author":"Kalia","year":"2021","journal-title":"Eur J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.016","article-title":"Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer","volume":"39","author":"Ehmsen","year":"2021","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200101000-00007","article-title":"Common variable immunodeficiency","volume":"321","author":"Sneller","year":"2001","journal-title":"Am J Med Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.07.002","article-title":"Exclusion of patients with a severe T-cell defect improves the definition of common variable immunodeficiency","volume":"4","author":"Bertinchamp","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/bies.950181009","article-title":"X-Linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease","volume":"18","author":"Mattsson","year":"1996","journal-title":"BioEssays"},{"key":"B16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","article-title":"A possible role for b cells in COVID-19? lesson from patients with agammaglobulinemia","volume":"146","author":"Quinti","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.08.040","article-title":"Secondary immunodeficiencies, including HIV infection","volume":"125","author":"Chinen","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.08.413","article-title":"Secondary immunodeficiencies","volume":"127","author":"Tuano","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.07.032","article-title":"Rituximab unveils hypogammaglobulinemia and immunodeficiency in children with autoimmune cytopenia","volume":"8","author":"Ottaviano","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"publisher","first-page":"102466","DOI":"10.1016\/j.autrev.2020.102466","article-title":"Post-rituximab immunoglobulin m (IgM) hypogammaglobulinemia","volume":"19","author":"Kridin","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-014-9995-5","article-title":"Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin","volume":"34","author":"Dhalla","year":"2014","journal-title":"J Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738915","article-title":"Secondary immunodeficiency in hematological malignancies: focus on multiple myeloma and chronic lymphocytic leukemia","volume":"12","author":"Allegra","year":"2021","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01352-z","article-title":"The 2022 update of IUIS phenotypical classification for human inborn errors of immunity","volume":"42","author":"Bousfiha","year":"2022","journal-title":"J Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1473-3099(21)00755-6","article-title":"Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products\u2013an update","volume":"22","author":"Romero","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1038\/s41467-022-30162-5","article-title":"Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against delta and omicron variants","volume":"13","author":"Belik","year":"2022","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.21203\/rs.3.rs-343388\/v1","article-title":"COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants","volume":"12","author":"Jalkanen","year":"2021","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.450","article-title":"COVID-19 infection in CVID patients: what we know so far","volume":"9","author":"Weifenbach","year":"2021","journal-title":"Immun Inflammation Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000789","article-title":"COVID-19 in complex common variable immunodeficiency patients affected by lung diseases","volume":"21","author":"Milito","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01283-9","article-title":"Neutralizing SARS-CoV-2 antibodies in commercial immunoglobulin products give patients with X-linked agammaglobulinemia limited passive immunity to the omicron variant","volume":"42","author":"Lindahl","year":"2022","journal-title":"J Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1099246","article-title":"Persistent T cell-mediated immune responses against omicron variants after the third COVID-19 mRNA vaccine dose","volume":"14","author":"Belik","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Sci (1979)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of a fourth dose of covid-19 mRNA vaccine against omicron","volume":"386","author":"Regev-Yochay","year":"2022","journal-title":"New Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13878","article-title":"Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL","volume":"110","author":"Benjamini","year":"2022","journal-title":"Eur J Haematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095954","article-title":"Memory T cell subsets, migration patterns, and tissue residence","volume":"31","author":"Mueller","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-437202","article-title":"Peptide length determines the outcome of TCR\/peptide-MHCI engagement","volume":"121","author":"Ekeruche-Makinde","year":"2013","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1146500\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T20:40:47Z","timestamp":1683751247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1146500\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2023.1146500"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1146500","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"article-number":"1146500"}}